Free Trial

Spire Healthcare Group (LON:SPI) Reaches New 52-Week High - Should You Buy?

Spire Healthcare Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Spire Healthcare shares reached a new 52-week high of GBX 249.50 and last traded at GBX 248.50, near the consensus price target of GBX 247.50.
  • Analyst sentiment remains a “Moderate Buy,” although Royal Bank of Canada downgraded the stock to “sector perform” and cut its price target from GBX 300 to GBX 250.
  • The company reported a quarterly loss of GBX 0.50 per share, alongside negative net margin and return on equity, while its high debt-to-equity ratio of 180.14 signals financial risk.
  • MarketBeat previews the top five stocks to own by December 1st.

Spire Healthcare Group plc (LON:SPI - Get Free Report)'s share price reached a new 52-week high on Monday. The company traded as high as GBX 249.50 and last traded at GBX 248.50, with a volume of 1,619,336 shares changing hands. The stock had previously closed at GBX 249.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada lowered Spire Healthcare Group to a "sector perform" rating and lowered their price objective for the company from GBX 300 to GBX 250 in a report on Monday, September 7th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Spire Healthcare Group presently has an average rating of "Moderate Buy" and a consensus price target of GBX 247.50.

View Our Latest Analysis on SPI

Spire Healthcare Group Stock Performance

The company has a market capitalization of £993.48 million, a P/E ratio of -496.00, a price-to-earnings-growth ratio of 1.06 and a beta of 0.93. The firm has a 50 day moving average price of GBX 244.51 and a two-hundred day moving average price of GBX 209.46. The company has a debt-to-equity ratio of 180.14, a quick ratio of 0.73 and a current ratio of 0.58.

Spire Healthcare Group (LON:SPI - Get Free Report) last issued its quarterly earnings data on Wednesday, September 30th. The company reported GBX (0.50) earnings per share for the quarter. Spire Healthcare Group had a negative return on equity of 0.26% and a negative net margin of 0.12%. On average, research analysts expect that Spire Healthcare Group plc will post 15.66 earnings per share for the current fiscal year.

About Spire Healthcare Group

(Get Free Report)

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spire Healthcare Group Right Now?

Before you consider Spire Healthcare Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.

While Spire Healthcare Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines